

Summary of status of development and availability of variant¹ influenza A(H1) candidate vaccine viruses*

* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test.

[National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

28 September 2017

Candidate vaccine viruses

Antigenic prototype*	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Ohio/9/2015 (H1N1)v	IDCDC-RG48A	Reverse genetics	CDC, USA	CDC, USA
A/Hunan/42443/2015 (H1N1)v	CNIC-1601	Conventional reassortant	CCDC, China	CCDC, China

Candidate vaccine viruses in preparation

Antigenic prototype	Type of virus or reassortant	Developing Institute	Status
A/Ohio/28/2016 (H1N2)v	Reverse Genetics	CDC, USA	Pending
A/Ohio/35/2016 (H1N2)v	Classical	NIBSC	Pending
A/Iowa/32/2016 (H1N2)v	Reverse Genetics	CDC, USA	Pending

* "Antigenic prototype" indicates that the antigenic characteristics of the CVV(s) in the table are antigenically like the virus listed.

Institutes contact details for candidate vaccine viruses orders/information:

CCDC: whocc-china@cnic.org.cn

CDC: dwentworth@cdc.gov (Subject: CVV request)

NIBSC: standards@nibsc.org or enquiries@nibsc.org

For other candidate vaccine viruses and potency testing reagents, please go to

<http://www.who.int/influenza/vaccines/virus/en/>

For general enquiries, please contact gisrs-whohq@who.int

¹ Joint FAO, OIE, WHO announcement of the standardization of influenza virus variants infecting humans: http://www.who.int/influenza/gisrs_laboratory/terminology_variant/en/